Table 4.

Characteristics of clinical trials on ω-3 FAs as the nutritional supplements in AP.

Reference	Subjects/regions	Dosage (g/kg BW/day)	Method of assessment	AD-EN or PN interval (h)	Duration of EN or PN (days)		Infectious complication (n/N)		Mortality (n/N)		DOS (days mean ± SD)
					Cont.	Interv.	Cont.	Interv.	Cont.	Interv.	Cont.	Interv.
Lasztity et al. (69)	28/Hungary	3.3 g/day	APACHE CT severity index	<24	17.57 ± 10.52	10.57 ± 6.70	–	–	1/14	2/14	19.28 ± 7.18	13.07 ± 6.70
Wang et al. (70)	40/China	0.2	APACHE	<72	5	5	5/20	3/20	2/20	0/20	70.5 ± 9.1	65.2 ± 7.3
Wang et al. (71)	28/China	0.2	APACHE CT severity index	<72	5	5	9/28	6/28	2/28	0/28	–	–

AD, the interval between admittance to ICU and start of enteral or parenteral nutrition; AP, acute pancreatitis; APACHE, acute physiology and chronic health evaluation; Cont., control; DOS, duration of hospital stay; EN, enteral nutrition; Interv., intervention; PN, parenteral nutrition; ω-3 FAs, omega-3 fatty acids.